J&J hunts for a Ry­bre­vant la­bel add just months af­ter rare lung can­cer ap­proval

J&J won’t be first to mar­ket with a treat­ment for non-small lung can­cer pa­tients who have a rare mu­ta­tion called ME­Tex14. But now, the com­pa­ny’s tak­ing a deep­er look at some Phase I da­ta in the hopes of po­si­tion­ing its drug Ry­bre­vant as an op­tion for those who be­come re­sis­tant to cur­rent­ly avail­able MET in­hibitors.

In the ME­Tex14 co­hort of the CHRYSALIS study (which re­cent­ly helped Janssen snag an ac­cel­er­at­ed ap­proval in NSCLC pa­tients with EGFR ex­on 20 in­ser­tion mu­ta­tions), 64% of pa­tients who took Ry­bre­vant saw a par­tial re­sponse, the drug­mak­er said on Thurs­day. A to­tal of 19 pa­tients with ME­Tex14 mu­ta­tions re­ceived ei­ther a high or low dose of Ry­bre­vant, and 14 of them were evalu­able. The re­spons­es were seen in both pa­tients who had and hadn’t re­ceived pri­or treat­ment, and the me­di­an time to first re­sponse was 4.1 months, ac­cord­ing to Janssen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER